Session Information
Date: Wednesday, September 25, 2019
Session Title: Non-Motor Symptoms
Session Time: 1:15pm-2:45pm
Location: Agora 3 West, Level 3
Objective: The efficacy of LCIG in advenced Parkinson Disease(aPD) is well known. The latter is especially for motor complications. But the non-motor symptoms and autonomic problems are often ignored. But these issues are very important for elderly and aPD patients with comorbidities.
Background: The aim of this study is to investigate the effects of LCIG on motor and autonomous signs. The best comparison of the results of the treatment with LCIG is carried with UPDRS Scores and with clinical observations.
Method: The patients of two centers (Selçuk University, Konya and Erciyes University, Kayseri Deparments of Neurology from Turkey) were participated in this study. A total number of patients were 22. All were followed from 2014 to early 2019. The clinical courses of these patients were evaluated in each quarter annually. Non motor symptoms and autonomic problems – urinary retention, frequency, orthostatic hypotension, salivation, constipation, impotance, REM period syndrome, willis – ekbom syndrome etc were all focused on. UPDRS scores were all evaluated at ON and OFF periods.
Results: The neccessity for antipsychotic usage was the most significant changes with LCIG. A similar result was faced with REM sleep behavior disorder, daytime sleepiness and orthostatic hypotension and sialorrhea. UPDRS scores with each subtitle of non-motor and autonomic signs were compared just before and after LCIG treatments.
Conclusion: LCIG treatment in aPD is very potent for the improvement of non-motor symptoms, it is also valid for autonomic system dysfuntions.
References: 1. Merola A, Romagnolo A, Comi C. et. al. Prevelance and burden of dysautonomia in advanced Parkinson’s disease. Mov Disord. 2017 May;32(5):796-797. 2. Antonini A, Poewe W, Chaudhuri KR, et. al GLORIA study co-investigators. Levodopa-carbidopa intestinal gel in advanced Parkinson’s: Final results of the GLORIA registry. Parkinsonism Relat Disord. 2017 Dec;45:13-20. 3.Wirdefeldt K, Odin P, Nyholm D. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson’s Disease: A Systematic Review. CNS Drugs. 2016 May;30(5):381-404.
To cite this abstract in AMA style:
H. Ekmekci, M. Gültekin. The effect of Levodopa-Carbidopa Intestinal Gel on Non-Motor Symptoms, Specificly Autonomic Dysfunctions [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/the-effect-of-levodopa-carbidopa-intestinal-gel-on-non-motor-symptoms-specificly-autonomic-dysfunctions/. Accessed June 14, 2025.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/the-effect-of-levodopa-carbidopa-intestinal-gel-on-non-motor-symptoms-specificly-autonomic-dysfunctions/